HR Execs on the Move

Galera Therapeutics

www.galeratx.com

 
Galera Therapeutics is focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.galeratx.com
  • 45 Liberty Boulevard Suite 230
    Malvern, PA USA 19355
  • Phone: 610.725.1500

Executives

Name Title Contact Details
Henning Thorsen
Vice President of Commercial Operations Profile
Elizabeth Turner
Vice President of Market Access Profile
Patrick Campbell
Vice President of Sales and Account Management Profile
Robert Beardsley
Chief Executive Officer Profile

Similar Companies

Perlan Therapeutics Inc

Perlan Therapeutics Inc is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

BestSelf

A change for the Best is here! Child & Adolescent Treatment Services and Lake Shore Behavioral Health are proud to become BestSelf Behavioral Health!

Ocusoft

Ocusoft is a Rosenberg, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Longboard Pharmaceuticals

Longboard Pharmaceuticals, Inc. (Longboard) is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. Longboard was formed in January 2020 by Arena Pharmaceuticals, Inc. (Arena) to advance a portfolio of centrally acting product candidates designed to be highly selective for specific G protein-coupled receptors (GPCRs). Longboard`s small molecule product candidates were discovered out of the same platform at Arena that represents a culmination of more than 20 years of GPCR research. Longboard is evaluating LP352, an oral, centrally acting, 5-hydroxytryptamine 2c receptor subtype superagonist, in development for the potential treatment of developmental and epileptic encephalopathies. Longboard is also evaluating LP143, a centrally acting, full cannabinoid type 2 receptor agonist, in development for the potential treatment of neurodegenerative diseases associated with neuroinflammation caused by microglial activation, and LP659, a centrally acting, sphingosine-1-phosphate receptor subtypes 1 and 5 modulator, in development for the potential treatment of central nervous system neuroinflammatory diseases.

Yamanouchi Pharma Ttechnologies

Yamanouchi Pharma Ttechnologies, Inc. is a Palo Alto, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.